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Craving Alcohol:  Genetic and 
Pharmacological Factors 
Kent Hutchison, Ph.D.
University of Colorado - Boulder
Objectives
Background and Long-Term Objective
Current treatments that target addiction are 
only modestly effective
Develop more effective treatments
Immediate Objectives
Characterize the behavioral and biological 
mechanisms associated with the etiology of 
addiction
Characterize genetic factors that influence 
these mechanisms
Characterizing Pharmacological and 
Genetic Mechanisms
Identify important behavioral phenotypes
Identify and test underlying biological mechanisms
Identify and test candidate genetic factors that may 
explain individual differences in these mechanisms 
and the behavioral phenotype
Informs a pharmacogenetic approach to the 
development and testing of new treatments for 
addictive disorders
Homer Simpson:  An iIlustration of 
Phenotypic Heterogeneity
Homer Simpson:  An iIlustration 
of Phenotypic Heterogeneity
Phenotypes of Interest
Cue elicited craving for alcohol
Pharmacological Mechanisms
Genetic Factors 
Treatment development
Subjective sensitivity to alcohol
Stimulatory and Euphoric Effects
Sedative Effects
Physiological sensitivity to alcohol
Startle Response
Heart Rate
Cue-Elicited Craving as a Phenotype
Cue-Elicited Craving
Clinically relevant
Associated with loss of control and relapse 
Target of numerous biological and behavioral 
interventions 
Can be studied in the laboratory
Triggered by environmental cues 
Triggered by small doses of alcohol
Alcoholics report powerful craving and loss of control 
after initial drink
Associated with a biological mechanism
dopamine neurotransmission in midbrain, prefrontal 
areas, D2 and D4 receptors
A personal description…
Study 1: Testing the Biological 
Mechanism
Would expect olanzapine (D2/D4 antagonist) to 
attenuate craving after a priming dose of alcohol
Methods
Sample - 26 heavy drinkers (Avg age= 23;  Drinking 
days = 16; Drinks/Day = 5.8)
Random assignment – Olanz (13), Pla (13)
Two experimental sessions – received 3 alcoholic 
drinks or 3 control drinks
Craving and reward assessed after each drink
Craving Results
Effect of Olanzapine on Alcohol-Elicited 
Craving 
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Hutchison et al., 2001, Psychopharmacology, 28, 234-239
Conclusions
Medication that blocks dopamine receptors
attenuates craving after alcohol consumption,
but does NOT influence the rewarding effects 
of alcohol consumption
Data consistent with distinction between 
“wanting” and “liking”
Data suggest that craving after alcohol 
consumption is a phenotype that is 
associated with the effect of alcohol on 
dopamine receptors
How to Advance a Candidate Genetic 
Factor?
Neuropharmacology
Do previous animal studies or human studies suggest a 
particular receptor subtype or mechanism that in turn 
suggests a particular gene? 
Is there a functional polymorphism in the gene? 
Is there a genetic variant that changes the expression or 
function of the receptor?
Has the variant been associated with other phenotypes?
Triangulate with Additional Evidence (e.g., Linkage 
Studies)
Is the gene in a location that has been linked to 
addiction?
A candidate genetic factor for 
alcohol craving
DRD4 VNTR polymorphism
D4 receptor gene
One of the variants may be associated with 
blunted intracellular response to dopamine
Has been associated with risk for ADHD
Close to place on chromosome 11 that has 
been linked to alcohol dependence
Study 2: Testing the Genetic 
Factor
Hypotheses
If the DRD4 VNTR expresses functional 
differences in the D4 receptor…
And if the D4 receptor is critical to the expression 
of craving
We would expect the DRD4 VNTR to moderate 
craving after alcohol consumption
Methods
74 subjects (23 women), mean age of 22, 11 
drinking days in last month, 4.8 drinks per day 
DNA -
Buccal cells (from cheek swabs) were collected 
48 bp DRD4 VNTR assayed
Participants were classified as DRD4 L (at least 1 
copy of 7 repeat allele; n=29) or DRD4 S (both 
alleles < 7 repeats; n=45) 
Classification based on in vitro evidence, molecular 
evidence, and previous association studies 
Alcohol challenge with successive drinks
Craving and reward were measured after each drink
Two experimental sessions – received 3 alcoholic 
drinks or 3 control drinks
Craving and the DRD4 VNTR
Figure 3a. Overall Effect
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Conclusions
DRD4 L individuals report significant 
increases in craving during consumption
No effect of the DRD4 VNTR on measures of 
reward 
Clinical Implications
DRD4 L individuals may be prone to high craving, 
loss of control and relapse in a drinking situation
Medications that target the D4 receptor may be 
effective for these individuals
Psychosocial approaches that emphasize 
abstinence (as opposed to harm avoidance) may 
be more appropriate
Study 3: A Combined test of the 
Mechanism and Polymorphism
Does olanzapine attenuate alcohol 
craving and is this effect more 
pronounced among DRD4 L individuals? 
If alcohol increases craving via activity at the D4 
receptor
And if individuals with the 7 repeat allele are 
particularly vulnerable to this effect
We would expect a D4 antagonist to block the 
ability of alcohol to trigger craving among these 
individuals
Methods
Subjects
Participants were recruited to participate in a study on 
the effects of alcohol and were paid $100
Subjects were included if they demonstrated moderate 
to heavy drinking, i.e., at least 2 times per week and 3 
drinks per episode (men) or 2 drinks per episode 
(women)
All subjects received a physical exam and were in 
good physical health
Female subjects were only included if they tested 
negative for pregnancy
6 subjects dropped out
Final sample included 67 subjects
Experimental Procedure
Subjects were randomly assigned to one of three 
medications: olanzapine (5 mg), cyproheptadine (4 
mg), and diphenhydramine (25 mg). 
Cyproheptadine and diphenhydramine were chosen to 
control for the effects of olanzapine on 5-HT2 and 
histamine receptors (see Table 1)
Diphenhydramine dropped due to differential sedation
Subjects consumed 5 doses of medication at intervals 
roughly equal to the half-life of the medication prior to 
the alcohol challenge
 Olanzapine Cyproheptadine Diphenhydramine 
Site of Action:    
D1 - D4 X   
5-HT2 X X  
H1, M1-5  X X X 
 
Hutchison, Wooden, Swift, Smolen, McGeary, Adler, & Paris, (in press), Neuropsychpharmacology
Hutchison, Wooden, Swift, Smolen, McGeary, Adler, & Paris, (in press), Neuropsychpharmacology
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Conclusions
Olanzapine generally decreased craving as compared to 
cyproheptadine
Olanzapine markedly decreased craving after alcohol 
consumption for DRD4 L individuals 
There were no effects for Medication or the DRD4 VNTR on 
measures of reward
The implication of these findings is that DRD4 L individuals 
may be biologically vulnerable to craving or loss of control 
after having an initial drink
Olanzapine or a similar medication may have a role in the 
treatment of alcohol dependence for these individuals
Olanzapine Feasibility Trial
Wait a minute, isn’t olanzapine the drug that…
Makes you sleep all day and makes you fat
Rationale
Preliminary studies suggest that olanzapine decreases craving for 
alcohol
Anecdotal evidence in the literature suggests that olanzapine (and its 
cousin clozapine) decrease substance use
Olanzapine is also a 5-HT3 antagonist very much like ondansetron
Ability to sleep at night and appetite stimulation may be positives
Aims
Determine whether 12 week trial of olanzapine is feasible as a 
treatment
Determine whether olanzapine shows some positive effects on craving 
and drinking behavior
Preliminary Findings
Methods
Many of the methods and measures adopted from Project 
COMBINE
>200 individuals were screened by phone, > 80 alcohol 
dependent subjects were medically screened
75 eligible and were randomly assigned to 12 weeks of 
treatment with olanzapine (2.5 to 5 mg) or a placebo
Medication management, MET, and urge coping skills
Cue exposure session after 2 weeks of treatment
Side effects
7 dropped out of olanzapine condition (2 drowsy, 1 weight 
gain), 10 out of placebo (1 “could not sleep”, 2 “not 
working”)
Reported side effects minimal – not significantly different
Average weight gain average is 6 lbs over 12 weeks
The DRD4 and Olanzapine Response
DRD4 S
1
2
3
4
5
Juice Alcohol
C
ra
vi
ng
 (A
U
Q
)
Olanzapine Placebo
DRD4 L
1
2
3
4
5
Juice Alcohol
C
ra
vi
ng
 (
A
U
Q
)
Olanzapine Placebo
Conclusions & Summary
Olanzapine reduces craving among DRD4 L 
individuals and appears to be well tolerated
Next treatment study will examine effects of 
olanzapine and a more intense psychosocial 
intervention on drinking with 1 year follow-up
Ultimately, olanzapine may point to better 
medications
This work is a methodological illustration of 
how to uncover genetic factors that may 
influence etiology and treatment response 
Other Alcohol Phenotypes
Alcohol Sensitivity
Subjective: Stimulation, Sedation
Physiological: startle response and heart rate
Candidate Genes
Pharmacologic Factors
Mu Opiate Receptors, GABA
Functional Variants
Functional variant in the OPRM1 gene that has been 
previously associated with substance use, stress 
response, and treatment response 
Variants in the GABRA6 & GABRA2 associated with 
alcohol related phenotypes
Alcohol Infusion Study
Designed to test whether the OPRM1 influences 
sensitivity to alcohol
Instead of drinking, individuals receive an 
intravenous infusion of ethanol
Allows us to control some of the variance in the 
pharmacokinetics
Individuals are assessed when their BAC 
reaches .02, .04, and .06
Allows us to control extraneous variables like 
subjective taste and expectancies
Effect of OPRM1 SNP (A/G)
Subjective High by OPRM1
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Future Efforts
Hippocampus
Amygdala
NAC
Mediodorsal
Thalamus
Medial OFC
Primary limitation is exclusive use of subjective craving
Must do a better job of conceptualizing and assessing the 
underlying biological mechanisms
Which brain structures underlie the expression of craving and 
are D4 receptors localized to these structures?
Functional Imaging Study
Aims 
To determine whether the activation of these structures correlates 
with subjective craving
To determine whether this activation is associated with the DRD4 
or other genetic factors
Methods
Block design that alternates 2 ml of alcohol with 2 ml of control 
beverage with and without visual stimuli
Collection of whole brain data
Can also examine influence of alcohol on other brain regions and 
examine the influence of other genetic factors 
Status of project
Pilot data demonstrating the feasibility has been collected
Grant is under review
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